“The authorization of our CTA in Canada is a significant milestone for our company, representing our first program to receive clearance by a regulatory body to enter the clinic and the first ever clinical trial to evaluate a therapy that rescues STMN2 expression in ALS...
QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....
The company also announced the formation of its Clinical Advisory Board, which will work closely with Dr. Genge on QurAlis’ clinical research and development programs in ALS and frontotemporal dementia (FTD) as the company prepares to move its pipeline to the clinical stage....
QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....
The financing was led by LS Polaris Innovation Fund, lead seed investor Mission BioCapital, INKEF Capital and the Dementia Discovery Fund, and co-led by Droia Ventures. Additional new investors include Mitsui Global Investment and Dolby Family Ventures, joined by investments from existing investors Amgen Ventures,...